ArticleBMC cancer2025
POLD3 knockdown effects on low-grade glioma: insights from bioinformatics and experimental validation.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLower-grade glioma (LGG) is a common primary brain tumor with potential progression to glioblastoma. Its development is closely linked to DNA damage repair. DNA polymerase delta subunit 3 (POLD3), a subunit of the DNA polymerase δ complex, participates in DNA replication and repair. POLD3 may act as a therapeutic target and prognostic biomarker in LGG.
methodsWe collected primary data from The Cancer Genome Atlas (TCGA), the Chinese Glioma Genome Atlas (CGGA), the Tumor Immune Estimation Resource (TIMER), and Gene Set Enrichment Analysis (GSEA). The CGGA dataset included messenger RNA (mRNA) sequencing and clinical data from 403 LGG cases; its microarray subset contained 142 additional cases. The TCGA dataset provided clinical data for 503 LGG cases. Employing bioinformatics tools, we investigated the correlation of POLD3 expression with the clinical characteristics, pathological features, survival outcomes, and tumor immune microenvironment in LGG. Subsequent functional validation of POLD3's impact in LGG was performed using both cellular and animal models.
resultsIntegrative analysis combining bioinformatics and experimental approaches revealed significant POLD3 overexpression in LGG. Elevated POLD3 levels exhibited significant associations with distinct clinicopathological features, altered immune cell infiltration profiles, and adverse clinical outcomes. Functionally, POLD3 was demonstrated to drive LGG cell proliferation, invasion, and modulate the tumor microenvironment.
conclusionThis study establishes POLD3 as a critical molecular determinant in LGG pathogenesis. Our findings position POLD3 as a promising multifaceted target, with significant implications for advancing LGG diagnostics, therapeutic development, immune modulation strategies, and prognostic assessment, thereby providing a fresh conceptual framework for understanding and managing this tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.